Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT06150222 (Retro-COSMOS) for Cancer, Cervical, Recurrence, Metastasis is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study (Retro-COSMOS) 350 International
Clinical Trial NCT06150222 (Retro-COSMOS) is an observational study for Cancer, Cervical, Recurrence, Metastasis and is currently not yet recruiting. Enrollment is planned to begin on 30 November 2023 and continue until the study accrues 350 participants. Led by Erasmus Medical Center, this study is expected to complete by 31 July 2027. The latest data from ClinicalTrials.gov was last updated on 1 December 2023.
Brief Summary
This multi centric international retrospective study aims to register patients with oligo metastatic and oligo recurrent cervical cancer. The study will register patients in planned period with an aim to analyse clinical outcomes with or without use of radiation in this setting.
Detailed Description
Detailed clinical protocol can be obtained by contacting the principal investigator.
Official Title
Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study (Retro-COSMOS). An EMBRACE Collaborative Initiative in Recurrent and Metastatic Cervix Cancer.
Conditions
Cancer, CervicalRecurrenceMetastasisOther Study IDs
- Retro-COSMOS
- MEC-2022-0355/ TMC-IEC-900891
NCT ID Number
Start Date (Actual)
2023-11-30
Last Update Posted
2023-12-01
Completion Date (Estimated)
2027-07-31
Enrollment (Estimated)
350
Study Type
Observational
Status
Not yet recruiting
Keywords
Reirradiation
OligoRecurrence
Oligometastasis
OligoRecurrence
Oligometastasis
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
N/A | Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.) The aim is to include all patients with (induced) oligo metastatic and oligo recurrent settings, irrespective of whether treated with concurrent chemoradiation, systemic chemotherapy, or with other locally directed therapies (like surgery, ablation, etc.) |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
3-year overall survival | To estimate overall survival of patients diagnosed with oligo-recurrent and (induced) oligo-metastatic cervix cancer. | From date of diagnosis of recurrence untill the date of death due to any cause or date of censoring at the last time the subject was known to be alive, whichever came first, assessed upto 3 years after initiation of the study |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
3-year Infield progression free survival | To estimate infield progression-free survival and progression-free interval of patients diagnosed with oligo-recurrent and (induced) oligo-metastatic cervix cancer. | From date of first disease progression to date of subsequent progression or death from any cause, whichever came first, assessed upto 3 years after initiation of the study |
3- year Progression free survival | To estimate overall progression-free survival of patients diagnosed with oligo-recurrent and (induced) oligo-metastatic cervix cancer. | From date of first disease progression to subsequent disease progression or death from any cause, whichever came first, assessed upto 3 years after initiation of the study |
Dose response relationship of nodal and visceral progressions | Radiation Dose-Response Curve will be generated for mean time to nodal and visceral progressions at different dose level | From date of start of treatment of disease progression, assessed upto 3 years |
Dose response relationship within setting of re-irradiation (infield progressions) | Radiation Dose-Response Curve will be generated for mean time to infield progression at different dose level | From date of start of treatment of disease progression, assessed upto 3 years |
Moderate to severe adverse events within the (induced) oligo-metastatic and oligo-recurrent setting ( including toxicity with targeted agents like bevacuzimab and pembrolizumab) | Number or percent of participants with treatment-related moderate to severe adverse events as assessed by CTCAE v4.0 (If available) | From date of start of treatment of recurrence to end of study, assessed upto 3 years after initiation of the study |
Report on various risk groups within oligo-metastatic and oligo-recurrent setting | Clinical, pathological, and treatment-related factors of patients recorded during the sudy will be used to develop multivariable risk models to identify risk factors and define various risk groups within oligo-metastatic and oligo-recurrent setting | From date of recurrence to end of study, assessed upto 3 years after initiation of the study |
Nomogram which correlates risk groups with expected outcomes within the (induced) oligo-metastatic and oligo-recurrent setting | Nomogram will be developed which could estimate the probability of a expected outcomes (overall survival, infield progression free survival, overall progression free survival) based on the risk group the patient belongs to within oligo-metastatic and oligo-recurrent setting. | From date of recurrence to end of study, assessed upto 3 years after initiation of the study |
Tissue based biomarkers | Sponsor Institute will facilitate storage of biopsy tissue of patients within oligo-metastatic and oligo-recurrent setting included in this study. In future, these tissue samples will be used for translational reseach in this field. | From date of start of recurrence to end of study, assessed upto 3 years after initiation of the study |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
Female
- Cervical cancer with (induced) oligo-metastatic and/or oligo-recurrent cervix cancer whether treated or not treated with radiation. These patients may have received previous treatment within or outside approved clinical trials/studies.
- Patients with poly-metastatic disease with good response to systemic chemotherapy and treated with radiation to recurrence or metastatic site.
- Patients treated with radical doses at the time of first diagnosis of oligo-metastasis/oligo-recurrence and present with further oligo-progression.
- Patients with oligo-metastasis or oligo-recurrence treated with other locally directed therapies (like surgery, ablation, etc.) are also permitted.
- Gynecological cancer other than cervical cancer
- Persistent Poly-metastatic disease post systemic treatment
- Receiving investigational new drugs at the time of relapse as part of other ongoing trials
- No clinical follow up after treatment
Erasmus Medical CenterTata Memorial CentreStudy Responsible Party
Prof. Dr. Remi A. Nout, Principal Investigator, Head of Department of Radiation Oncology, Erasmus Medical Center
Study Central Contact
Contact: Rene Vernhout, MSc, +31 107041341, [email protected]
No location data.